Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $100 price target.
October 30, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Intra-Cellular Therapies and maintained a $100 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $100 price target by a reputable analyst suggests a positive outlook for ITCI, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100